Fe3O4-solamargine induces apoptosis and inhibits metastasis of pancreatic cancer cells

Xie,Xiaodong; Zhang,Xiuming; Chen,Jun; Tang,Xun; Wang,Meiqin; Zhang,Lei; Guo,Zhen; Shen,Wenrong

doi:10.3892/ijo.2018.4637

Fe3O4-solamargine induces apoptosis and inhibits metastasis of pancreatic cancer cells

Authors:
- Xiaodong Xie
- Xiuming Zhang
- Jun Chen
- Xun Tang
- Meiqin Wang
- Lei Zhang
- Zhen Guo
- Wenrong Shen
View Affiliations

Affiliations: Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China, Department of Intervention, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China, Department of Clinical Laboratory, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China
Published online on: November 19, 2018 https://doi.org/10.3892/ijo.2018.4637
Pages: 905-915
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fe3O4-magnetic liposome (MLP) can deliver drugs to target tissues and can increase drug efficacy. The present study aimed to investigate the effects of solamargine (SM) and Fe3O4-SM in pancreatic cancer (PC). Cell viability was detected using a Cell Counting kit‑8 assay. Apoptosis and cell cycle progression was tested using a flow cytometry assay. A scratch assay was used to examine cell metastasis. Quantitative polymerase chain reaction, western blot analysis or immunohistochemical analysis were performed to determine the expression of target factors. Magnetic resonance imagining (MRI) and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling were conducted to detect tumor growth and apoptosis in vivo, respectively. It was demonstrated that Fe3O4-SM inhibited cancer cell growth via a slow release of SM over an extended period of time. SM was revealed to induce apoptosis and cell cycle arrest. Furthermore, SM decreased the expression of X-linked inhibitor of apoptosis, Survivin, Ki‑67, proliferating cell nuclear antigen and cyclin D1, but increased the activity of caspase-3. It was also observed that SM inhibited tumor cell metastasis by modulating the expression of matrix metalloproteinase (MMP)-2 and TIMP metallopeptidase inhibitor-2. Furthermore, the phosphorylation of protein kinase B and mechanistic target of rapamycin was suppressed by SM. Notably, the effect of SM was enhanced by Fe3O4-SM. The malignant growth of PC was decreased by SM in vivo. Furthermore, the expression of Ki‑67 was decreased by SM and Fe3O4-SM. Additionally, cell apoptosis was increased in the Fe3O4-SM group, compared with the SM group. The present study illustrated the antitumor effect and action mechanism produced by SM. Additionally, it was demonstrated that Fe3O4-SM was more effective than SM in protecting against PC.

View Figures

View References

1	Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P and Pezzilli R: Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 24:349–358. 2010. View Article : Google Scholar : PubMed/NCBI
2	No authors listed. The World Cancer Report - the major findings. Cent Eur J Public Health. 11:177–179. 2003.
3	GBD 2016 Causes of Death Collaborators: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 390:1151–1210. 2017. View Article : Google Scholar
4	Kleeff J, Michalski C, Friess H and Büchler MW: Pancreatic cancer: From bench to 5-year survival. Pancreas. 33:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
5	Schiff E and Ben-Arye E: Complementary therapies for side effects of chemotherapy and radiotherapy in the upper gastrointestinal system. Eur J Integr Med. 3:11–16. 2011. View Article : Google Scholar
6	Gupta AK and Gupta M: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 26:3995–4021. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gan ZJJ: Preparation of magnetic monodisperse nanoparticles and biopolymer assembly on the magnetic carriers. Huaxue Jinzhan. 17:978–986. 2005.
8	Gallo JM, Hafeli U, Lübbe AS, et al: Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56:4694–4701. 1996. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56:4686–4693. 1996. Cancer Res. 57:3063–3065. 1997.
9	Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, et al: Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56:4686–4693. 1996.
10	Sabaté R, Barnadas-Rodríguez R, Callejas-Fernández J, Hidalgo-Alvarez R and Estelrich J: Preparation and characterization of extruded magnetoliposomes. Int J Pharm. 347:156–162. 2008. View Article : Google Scholar
11	Fricker J: Drugs with a magnetic attraction to tumours. Drug Discov Today. 6:387–389. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kohler N, Sun C, Wang J and Zhang M: Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 21:8858–8864. 2005. View Article : Google Scholar : PubMed/NCBI
13	Cinteza LO, Ohulchanskyy TY, Sahoo Y, Bergey EJ, Pandey RK and Prasad PN: Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. Mol Pharm. 3:415–423. 2006. View Article : Google Scholar : PubMed/NCBI
14	Novikov VV, Ponomarev VO, Novikov GV, Kuvichkin VV, Iablokova EV and Fesenko EE: Effects and molecular mechanisms of the biological action of weak and extremely weak magnetic fields. Biofizika. 55:565–572. 2010.
15	Sato K, Watanabe Y, Horiuchi A, Yukumi S, Doi T, Yoshida M, Yamamoto Y, Maehara T, Naohara T and Kawachi K: Novel tumor-ablation device for liver tumors utilizing heat energy generated under an alternating magnetic field. J Gastroenterol Hepatol. 23:1105–1111. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chertok B, David AE and Yang VC: Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 155:393–399. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lu ZR, Ye F and Vaidya A: Polymer platforms for drug delivery and biomedical imaging. J Control Release. 122:269–277. 2007. View Article : Google Scholar : PubMed/NCBI
18	Gan KH, Lin CN and Won SJ: Cytotoxic principles and their derivatives of Formosan Solanum plants. J Nat Prod. 56:15–21. 1993. View Article : Google Scholar : PubMed/NCBI
19	Alzérreca A and Hart G: Molluscicidal steroid glycoalkaloids possessing stereoisomeric spirosolane structures. Toxicol Lett. 12:151–155. 1982. View Article : Google Scholar : PubMed/NCBI
20	Xie X, Zhu H, Yang H, Huang W, Wu Y, Wang Y, Luo Y, Wang D and Shao G: Solamargine triggers hepatoma cell death through apoptosis. Oncol Lett. 10:168–174. 2015. View Article : Google Scholar : PubMed/NCBI
21	Kuo KW, Hsu SH, Li YP, Lin WL, Liu LF, Chang LC, Lin CC, Lin CN and Sheu HM: Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem Pharmacol. 60:1865–1873. 2000. View Article : Google Scholar : PubMed/NCBI
22	Liang CH, Shiu LY, Chang LC, Sheu HM and Kuo KW: Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol Nutr Food Res. 51:999–1005. 2007. View Article : Google Scholar : PubMed/NCBI
23	Yang X, Zhang X, Ma Y, Huang Y, Wang Y and Chen Y: Superparamagnetic graphene oxide-Fe₃O₄ nanoparticles hybrid for controlled targeted drug carriers. J Mater Chem. 19:2710–2714. 2009. View Article : Google Scholar
24	Liang C-C, Park AY and Guan J-L: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
26	van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lütje S, McBride WJ, Oyen WJ and Boerman OC: Pretargeted radioim-munotherapy of prostate cancer with an anti-TROP-2xanti-HSG bispecific antibody and a (177)Lu-labeled peptide. Cancer Biother Radiopharm. 29:323–329. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liao MY, Kuo MY, Lu TY, Wang YP and Wu HC: Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer. Int J Oncol. 46:1788–1800. 2015. View Article : Google Scholar : PubMed/NCBI
28	Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ and Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 135:81–87; discussion 88. 2000. View Article : Google Scholar : PubMed/NCBI
29	Kalra AV and Campbell RB: Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm Res. 23:2809–2817. 2006. View Article : Google Scholar : PubMed/NCBI
30	Zhang L, Chang CJ, Bacus SS and Hung M-C: Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 55:3890–3896. 1995.PubMed/NCBI
31	Shiu LY, Chang LC, Liang CH, Huang YS, Sheu HM and Kuo KW: Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol. 45:2155–2164. 2007. View Article : Google Scholar : PubMed/NCBI
32	Liu LF, Liang CH, Shiu LY, Lin WL, Lin CC and Kuo KW: Action of solamargine on human lung cancer cells - enhancement of the susceptibility of cancer cells to TNFs. FEBS Lett. 577:67–74. 2004. View Article : Google Scholar : PubMed/NCBI
33	Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell. 78:539–542. 1994. View Article : Google Scholar : PubMed/NCBI
34	Ho A and Dowdy SF: Regulation of G₁ cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev. 12:47–52. 2002. View Article : Google Scholar : PubMed/NCBI
35	Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, et al: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 5:25–35. 2004. View Article : Google Scholar : PubMed/NCBI
36	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
37	Coates PJ, Hales SA and Hall PA: The association between cell proliferation and apoptosis: Studies using the cell cycle-associated proteins Ki67 and DNA polymerase alpha. J Pathol. 178:71–77. 1996. View Article : Google Scholar : PubMed/NCBI
38	Ouhtit A, Gaur RL, Abdraboh M, Ireland SK, Rao PN, Raj SG, Al-Riyami H, Shanmuganathan S, Gupta I, Murthy SN, et al: Simultaneous inhibition of cell-cycle, proliferation, survival, metastatic pathways and induction of apoptosis in breast cancer cells by a phytochemical super-cocktail: Genes that underpin its mode of action. J Cancer. 4:703–715. 2013. View Article : Google Scholar : PubMed/NCBI
39	Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M and Moeinifard M: Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Tumour Biol. 34:1085–1095. 2013. View Article : Google Scholar : PubMed/NCBI
40	Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
41	Fang W, Li H, Kong L, Niu G, Gao Q, Zhou K, Zheng J and Wu B: Role of matrix metalloproteinases (MMPs) in tumor invasion and metastasis: Serial studies on MMPs and TIMPs. Beijing Da Xue Xue Bao Yi Xue Ban. 35:441–443. 2003.In Chinese. PubMed/NCBI
42	Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS and Lakka S: Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther. 5:2289–2299. 2006. View Article : Google Scholar : PubMed/NCBI
43	Luca M, Huang S, Gershenwald JE, Singh RK, Reich R and Bar-Eli M: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 151:1105–1113. 1997.PubMed/NCBI
44	Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
45	Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
46	Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
47	Kitano H, Chung JY, Ylaya K, Conway C, Takikita M, Fukuoka J, Doki Y, Hanaoka J and Hewitt SM: Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. J Histochem Cytochem. 62:335–346. 2014. View Article : Google Scholar : PubMed/NCBI
48	Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
49	Takahashi M and Kohda H: Diagnostic utility of magnetic resonance imaging in malignant melanoma. J Am Acad Dermatol. 27:51–54. 1992. View Article : Google Scholar : PubMed/NCBI